Skip to main content

Table 1 Clinical variables in patients with high and low expression of MFN2

From: Mitofusin-2 acts as biomarker for predicting poor prognosis in hepatitis B virus related hepatocellular carcinoma

Variable MFN2 expression P value
High expression Low expression
Sample size 33 74  
Age, years 0.179
  > 50 15 (45.5%) 44 (59.5%)  
  ≤ 50 18 (54.5%) 30 (40.5%)  
Gender 0.844
 Male 29 (87.9%) 64 (86.5%)  
 Female 4 (12.1%) 10 (13.5%)  
AFP, ng/mL 0.420
  < 20 10 (30.3%) 17 (23.0%)  
  ≥ 20 23 (69.7%) 57 (77.0%)  
Cirrhosis 0.049
 Yes 30 (90.9%) 55 (74.3%)  
 No 3 (9.1%) 19 (25.7%)  
Tumor size, cm 0.128
  < 5 9 (27.3%) 11 (14.9%)  
  ≥ 5 24 (72.7%) 63 (85.1%)  
Differentiation 0.202
 Well-moderate 6 (18.2%) 7 (9.5%)  
 Poor-undifferentiated 27 (81.8%) 67 (90.5%)  
TNM stage 0.196
 I–II 15 (45.5%) 24 (32.4%)  
 III–IV 18 (54.5%) 50 (67.6%)  
Vascular invasion 0.192
 Yes 4 (12.1%) 17 (23.0%)  
 No 29 (87.9%) 57 (77.0%)  
  1. Abbreviations: MFN2 Mitofusin-2, AFP alpha-fetoprotein